Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688670 Jiangsu Gdk Biological Technology
44.550
-1.010-2.22%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Total operating revenue
-36.83% 220.36M -48.91% 16.4M -58.50% 12.47M -33.41% 392.27M
Operating revenue
-36.83% 220.36M -48.91% 16.4M -58.50% 12.47M -33.41% 392.27M
Total operating cost
-21.60% 173.31M -19.14% 52.65M -43.83% 21.15M -27.64% 269.37M
Operating cost
-14.02% 32.54M -61.51% 1.81M -68.17% 1.33M -22.39% 57.18M
Operating tax surcharges
-24.52% 2.07M -44.87% 603.76K -19.38% 393.68K -0.99% 3.56M
Operating expense
-33.48% 76.7M -40.00% 7.13M -57.24% 5.1M -44.40% 116.27M
Administration expense
31.16% 37.65M 24.87% 25.21M -2.87% 11.67M 4.30% 49.97M
Financial expense
-106.67% -506.69K -107.67% -515.98K -109.59% -306.9K -24.19% 7.12M
-Interest expense (Financial expense)
-91.52% 831.06K -94.11% 430.59K -95.08% 166.25K 2.23% 9.85M
-Interest Income (Financial expense)
56.59% 1.28M 64.12% 963.89K 158.57% 477.74K 933.41% 2.75M
Research and development
-13.86% 24.86M -10.20% 18.42M -49.28% 2.95M 23.58% 35.26M
Credit Impairment Loss
109.91% 249.1K -2.74% 11.1M -39.07% 3.57M 91.90% -1.26M
Asset Impairment Loss
80.11% -2.58M 98.44% -155.92K 97.96% -118.19K -5,008.12% -57.94M
Other net revenue
0 0 0 0
Fair value change income
-- -826.69K -- 1.75M -- 859.17K -- 2.31M
Invest income
1,071.91% 11.28M 1,121.90% 6.29M 2,030.23% 3.86M 1,121.93% 4.95M
Asset deal income
-- -- -- -- -- -- -2,000.51% -46.76K
Other revenue
-1.62% 7.19M 34.90% 5.28M -81.19% 226.54K 16.68% 13.05M
Operating profit
-48.26% 62.36M 55.91% -11.99M 95.47% -281.07K -60.34% 83.97M
Add:Non operating Income
48.97% 33.18K 96.22% 20.08K 82.76% 10.66K 58.45% 37.53K
Less:Non operating expense
-- 81.4K -- -- -- -- -99.62% 3.18K
Total profit
-48.31% 62.31M 55.97% -11.97M 95.64% -270.42K -60.18% 84M
Less:Income tax cost
-67.30% 6.7M 236.42% 5.29M 362.76% 2.37M -97.25% 1.54M
Net profit
-44.43% 55.62M FPtoL -17.26M FPtoL -2.64M -46.79% 82.46M
Net profit from continuing operation
-44.43% 55.62M 25.95% -17.26M 50.11% -2.64M -46.79% 82.46M
Net profit of parent company owners
-44.43% 55.62M 25.95% -17.26M 50.11% -2.64M -46.79% 82.46M
Earning per share
Basic earning per share
-55.32% 0.63 42.86% -0.2 66.67% -0.03 -53.19% 1.1
Diluted earning per share
-55.32% 0.63 42.86% -0.2 66.67% -0.03 -53.19% 1.1
Other composite income
Total composite income
-44.43% 55.62M 25.95% -17.26M 50.11% -2.64M -46.79% 82.46M
Total composite income of parent company owners
-44.43% 55.62M 25.95% -17.26M 50.11% -2.64M -46.79% 82.46M
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company was founded in December 2008, with a registered capital of 88 million yuan. The company is located in Taizhou, Jiangsu Province, a famous city with a long history in the Yangtze River Delta, and is located in the national pharmaceutical high-tech industry and technology development zone. The company is a biological high-tech enterprise integrating scientific research, production, management and service of human vaccine, with perfect technical development strength, technical level, production and testing equipment, scientific and standardized management and quality assurance system. The company focuses on the R & D, production and sales of human vaccines. The main products include 10 kinds of human vaccine products for the prevention of five infectious diseases, including influenza, rabies, chicken pox, herpes zoster and pneumonia.
CEO: Jun Yu
Market: --
Listing Date: 08/02/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist